Sanofi SA

SNW

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

Our view of BHP after June quarter results

Record copper volumes are reported.
stocks

James Hardie transfers of share listing to New York Stock Exchange

The change is a result of the controversial Azek acquisition.
stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,926.2080.60-0.89%
CAC 407,799.6723.00-0.29%
DAX 4024,261.6327.88-0.11%
Dow JONES (US)44,342.19142.30-0.32%
FTSE 1008,999.937.810.09%
HKSE24,964.30138.640.56%
NASDAQ20,895.6510.010.05%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,961.5181.110.63%
S&P 5006,296.790.57-0.01%
S&P/ASX 2008,668.2089.00-1.02%
SSE Composite Index3,559.7925.310.72%

Market Movers